ARTICLE | Company News
Bachem, Jerini deal
March 22, 2004 8:00 AM UTC
Bachem will provide cGMP manufacturing for Jerini's Icatibant for clinical trials. Icatibant ( JE049) is a selective peptidomimetic bradykinin BK2 receptor antagonist. The compound is in Phase II stud...